吲哚布芬与阿司匹林在心血管疾病患者中的预防和治疗效果及药物经济学评价比较研究

Comparative study on the preventive and therapeutic effects and pharmacoeconomic evaluation of indobufen and aspirin in patients with cardiovascular diseases

目的比较吲哚布芬与阿司匹林在心血管疾病患者中的预防与治疗作用及药物经济学评价。方法选取2020年1—12月于福建医科大学附属福州市第一医院及福建医科大学附属福清市医院住院收治的197例心血管疾病患者作为研究对象,根据不同治疗药物分为阿司匹林组(n=124)与吲哚布芬组(n=73),再根据使用药物目的分为阿司匹林预防组(n=62)、阿司匹林治疗组(n=62)、吲哚布芬预防组(n=55),吲哚布芬治疗组(n=18)。阿司匹林组给予阿司匹林预防、治疗,吲哚布芬组给予吲哚布芬预防、治疗,比较各组治疗前后血小板计数、住院时间、每天抗血小板药费用、不良反应发生情况。结果各组用药前后血小板计数比较差异无统计学意义;用药后,阿司匹林治疗组血小板计数低于用药前,差异有统计学意义(P<0.05),其他各组组内用药前后比较差异均无统计学意义。各组住院时间比较差异无统计学意义;吲哚布芬预防组、吲哚布芬治疗组每天抗血小板药费用均高于阿司匹林预防组、阿司匹林治疗组,且吲哚布芬治疗组高于吲哚布芬预防组,差异有统计学差异(P<0.05),阿司匹林预防组与阿司匹林治疗组每天抗血小板药费用比较差异无统计学意义。吲哚布芬组不良反应发生率为1.37%,低于阿司匹林组不良反应发生率的10.48%,,但两组比较差异无统计学意义。结论与阿司匹林比较,吲哚布芬治疗心血管疾病患者的不良反应发生率较低,治疗成本高,还需进行多中心大样本临床试验验证吲哚布芬是否可作为阿司匹林的替代。

Objective To compare the preventive and therapeutic effects and pharmacoeconomic evaluation of indobufen and aspirin in patients with cardiovascular diseases.Methods 197 patients with cardiovascular diseases admitted to Fuzhou First General Hospital Affiliated with Fujian Medical University and Fuqing Hospital Affiliated to Fujian Medical University from January to December 2020 were selected as the study subjects,and they were divided into the aspirin group(n=124)and the indobufen group(n=73)according to different therapeutic drugs,and they were divided into the aspirin prevention group(n=62),the aspirin treatment group(n=62),the indobufen prevention group(n=55)and the indobufen treatment group(n=18)according to the purpose of drug use.The aspirin group was given aspirin prevention and treatment,and the indobufen group was given indobufen prevention and treatment,the platelet count before and after treatment,length of hospital stay,daily cost of antiplatelet drugs and incidence of adverse reactions were compared among the each group.Results There was no significant difference in platelet count before and after medication among all groups;after medication,platelet count in the aspirin treatment group was lower than before medication,the difference was statistically significant(P<0.05),and there was no statistically significant difference before and after medication in other groups.There was no significant difference in the length of hospital stay among all groups;the daily antiplatelet drug cost of in the indobufen prevention group and indobufen treatment group was higher than that in the aspirin prevention group and aspirin treatment group,and the indobufen treatment group was higher than the indobufen prevention group,and the differences were statistically significant(P<0.05);there was no statistically significant difference between the aspirin prevention group and the aspirin treatment group.The incidence of adverse reactions in the indobufen group was 1.37%,which was lower than 10.48%in the aspirin group,but there was no significant difference between the two groups.Conclusion Compared with aspirin,indobufen has a lower incidence of adverse reactions and higher cost in the treatment of patients with cardiovascular diseases,and multi-center and large-sample clinical trials are needed to verify whether indobufen can be used as an alternative to aspirin.